|
⚲
|
| Message |
|---|
| Happy Holidays!! thanks for using AUM13F!! |
| Sofinnova Investments Inc
✚
|
|
|---|---|
| CRD # | 160297 |
| SEC # | 801-110134 |
| CIK # | 0001631134 |
| AUM | $3.8 B (2025-03-20) |
| Employees | 40 (50% Investors, 0% Brokers) |
| Phone | 650-681-8420 |
| Address | 3000 Sand Hill Road Menlo Park, CA 94025 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Natera Inc | 0.3 | ||
| Gilead Sciences Inc | 0.1 | ||
| Lilly Eli & Co | 0.1 | ||
| Jazz Pharmaceuticals Inc | 0.1 | ||
| Vera Therapeutics Inc | 0.1 | ||
| Rhythm Pharmaceuticals Inc | 0.1 | ||
| AbbVie Inc | 0.0 | ||
| Boston Scientific Corp | 0.0 | ||
| Roivant Sciences Ltd | 0.0 | ||
| Dexcom Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold ($M) | AUM ($M) |
|---|---|---|---|---|
| VC | Sofinnova Venture Partners XII LP | [2025-03-20] | 0.0 | 0.0 |
| HF | Sofinnova Bioequities Enhanced Master Fund LP | [2023-03-29] | 35.7 | 834.3 |
| HF | Sofinnova Synergy Master Fund LP | [2022-03-30] | 4.9 | 5.7 |
| VC | Sofinnova Venture Partners Xi LP | [2022-03-30] | 500.0 | 218.6 |
| HF | Sofinnova Bioequities Master Fund Ltd | [2017-03-03] | 363.7 | 172.0 |
| VC | Sofinnova Venture Partners X LP | [2017-03-03] | 595.5 | 293.9 |
| VC | Sofinnova Venture Partners IX LP | [2015-03-27] | 0.0 | 320.2 |
| VC | 80 | [2014-03-27] | 65.3 | 2.2 |
| VC | 194 | 2012-03-30 | 0.0 | |
| VC | 294 | 2012-03-30 | 0.2 | |
| VC | 94 | 2012-03-30 | 0.0 | |
| VC | Sofinnova Venture Affiliates VI LP | 2012-03-30 | 0.0 | |
| VC | Sofinnova Venture Partners VI GmbH & Co KG | 2012-03-30 | 0.0 | |
| VC | Sofinnova Venture Partners VIII LP | [2012-03-30] | 440.0 | 7.7 |
| VC | Sofinnova Venture Partners VII LP | 2012-03-30 | 150.4 | |
| VC | Sofinnova Venture Partners VI LP | 2012-03-30 | 0.0 |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 10 | 2.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 8 | 1.7 |
| (n) Other | 0 | 0.0 |
| Total | 18 | 3.8 |
| By Discretionary | ||
| Discretionary | 18 | 3.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 18 | 3.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 2.3 | |
| United States Persons | 1.5 | |
| Total | 18 | 3.8 |
| Form D Directors | # Filings | # Firms | 2011 - 2025 | |
|---|---|---|---|---|
| Garheng Kong | 59 | |||
| James Healy | 49 | |||
| Srinivas Akkaraju | 27 | |||
| Michael Powell | 52 | |||
| Anand Mehra | 20 | |||
| Maha Katabi | 12 | |||
| Sofinnova Investments Inc | 3 | |||
| Eric Delbridge | 2 | |||
| Sarah Bhagat | 2 | |||
| Sofinnova Bioequities GP LLC | 2 | |||
| View All | ||||
| EDGAR Form | CIK | 2011 - 2025 |
|---|---|---|
| 13F-HR | [0001631134] | |
| SC 13G | [0001631134] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Sofinnova Investments Inc | Marinus Pharmaceuticals Inc | [2024-11-14] |
| Sofinnova Investments Inc | Otonomy Inc | [2021-02-16] |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
North Reef Capital Management LP
✚
|
CA | 3.9 |
|
Summit Partners Public Asset Management LLC
✚
|
MA | 3.9 |
|
Tages Capital LLP
✚
|
3.8 | |
|
Ghisallo Capital Management LLC
✚
|
MA | 3.8 |
|
Trium Capital LLP
✚
|
3.8 | |
|
Elementum Advisors LLC
✚
|
IL | 3.7 |
|
Stonehill Capital Management LLC
✚
|
NY | 3.7 |
|
Performa Limited US LLC
✚
|
SC | 3.7 |
|
Camber Capital Management LP
✚
|
MA | 3.7 |
|
DME Capital Management LP
✚
|
NY | 3.7 |